Tecovirimat antiviral drug can shorten the duration of monkeypox disease

Tecovirimate antiviral may improve the results of people infected with monkeypox, a recent study in Britain suggests.

The small retrospective observational study, published in The Lancet Infectious Diseases, included 7 patients who were treated for monkeypox in high-impact infectious disease centers in the UK between August 15, 2018 and August 10, 2018. September 2021 and aimed to describe the clinical course of the disease. the disease and the response to new antiviral therapies.

“The single most important outcome is the excellent clinical and virological response to oral antiviral tecovirimat in a monkeypox patient who received this agent,” lead author Hugh Adler, PhD, of Liverpool, told Contagion University Hospitals NHS Foundation Trust. “We definitely need prospective, well-leveraged studies to validate this finding, but it’s a strong signal and may be helpful for doctors who manage monkeypox patients in the current outbreak in the Western Hemisphere.”

Three patients were treated with 200 mg of brincidofovir weekly before developing elevated liver enzymes and finishing treatment. One patient received 600 mg of tecovirimate twice daily for two weeks and experienced a shorter duration of disease and the spread of the virus.

The study included patients who tested positive after traveling from Nigeria along with transmission to a healthcare worker and within a family home. All seven patients in the study developed skin lesions and all recovered completely.

“We were surprised to find positive PCR results for monkeypox in the blood and upper respiratory swabs, and we were especially surprised that throat swabs remained positive in PCR long after the eruption resolution in some cases, “Adler said. “We still don’t know the implications for infection control tips, etc. (after all, don’t forget that patients with COVID can stay positive for PCR for weeks even though they’re no longer infectious), but it needs to be taken into account when managing patients in the current outbreak and it requires dedicated research (for example, with viral culture) to resolve the issue once and for all. “

Three patients in the study spent more than three weeks isolated due to prolonged positivity. The disease was mild in all patients involved in the study, with none suffering from pneumonia or sepsis. Unexpected symptoms included a mild relapse six weeks after discharge in one patient and a deep tissue abscess that required drainage in another. Isolation caused low mood in patients.

We wanted to draw attention to the prolonged illness and hospitalization that our patients experienced, even with the “uncomplicated” monkeypox, so that health care providers could be prepared to provide psychological support to patients with this infection and for policy makers to consider whether self-isolation at home is an option for selected patients, “Adler said. “And most importantly, we want health care providers and readers everywhere to know that monkeypox is still a major public health problem in West and Central Africa, where there is an unmet need. of the most evidence-based antiviral treatments, vaccines, and infection control protocols.

Smallpox is endemic in Africa, but global health officials have been closely monitoring the recent outbreak of the disease outside Africa. About 300 cases of smallpox have been reported in a dozen countries.

“Doctors, including the authorship of this paper, continue to be involved in the clinical and public health response to the unprecedented outbreak of smallpox in the UK, Europe and beyond, and I am confident that this will be monitored.” , said Adler. “There are plans to conduct further research to explain our finding of positive viral PCR testing for monkeypox in upper respiratory throat swabs and to understand the implications of infection control. And internationally I am pleased that there is there is a recruitment test in the Democratic Republic of the Congo to study the role of smallpox vaccination for healthcare staff treating smallpox patients, and an expanded tecovirimat access program in the Central African Republic. “

Leave a Comment

Your email address will not be published. Required fields are marked *